Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Dx Firms ACT Genomics, Sanomics Merge

NEW YORK – Cancer diagnostic firm ACT Genomics announced on Monday that it has merged with lung cancer diagnostic company Sanomics.

Financial and other terms of the deal were not disclosed.

Both companies are part of the Hong Kong government's business incubator Hong Kong Science and Technology Parks, ACT Genomics said in a statement. The combined firm will offer tissue and liquid-based tests using next-generation sequencing, digital PCR, and gene chips, it added.

It will also provide services for cancer types at different stages in clinical applications and help pharmaceutical companies develop companion diagnostics for drug discovery.

The combined company has four laboratories, with two in Hong Kong, one in Thailand, and one in Taipei, Taiwan. The Hong Kong and Taipei laboratories are accredited by the College of American Pathologists.

The group also has a CAP-accredited lab in Kanagawa, Japan, under its joint venture with Canon Medical Systems, and an additional immunohistochemistry and flow cytometry lab in Taipei under its joint venture with Cerba Research.

Tony Mok, chairman of Sanomics, has become chairman of ACT Genomics with the merger. In a statement, Mok said the team "is ready to make meaningful contributions to the enlarged group with our technical expertise, especially in the field of lung cancer, as well as firsthand clinical experience." He added that the combined resources "will enable us to provide more comprehensive solutions and better services to clinicians."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.